Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the gynecologie oncology group

H. B. Muss, B. N. Bundy, F. T. Given, F. B. Stehman

Research output: Contribution to journalArticle

4 Scopus citations


Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95% confidence intervals for response ≤ 19%). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1.000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.

Original languageEnglish (US)
Pages (from-to)117-118
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
StatePublished - Jan 1 1990


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this